Total Funding
95
90
Total FundingSeries D raised
Growth Score
16 pts
Heat Score
34 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10634
Periotherapia is a drug discovery business with triple negative breast cancer as the first indication.
- Taniyama Yoshiaki: President & CEO
About the Company
Periotherapia is a Drug discovery business with triple negative breast cancer as the first indication. Periotherapia aims to selectively inhibit only ASV that is involved in pathogenesis without inhibiting physiological ASV in chronic diseases such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. is.
